Hetero Labs Limited — Fluticasone Exporter Profile
Indian Pharmaceutical Exporter · #2 for Fluticasone · $4.5M export value · DGFT Verified
Hetero Labs Limited is the #2 Indian exporter of Fluticasone with $4.5M in export value and 112 verified shipments. Hetero Labs Limited holds a 2.2% market share in Fluticasone exports across 4 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.
Hetero Labs Limited — Fluticasone Export Profile: Buyers & Destinations
Where Does Hetero Labs Limited Export Fluticasone?
| Country | Value | Shipments | Share |
|---|---|---|---|
| CHILE | $3.5M | 102 | 90.5% |
| MOROCCO | $326.3K | 7 | 8.5% |
| DOMINICAN REPULIC | $31.5K | 2 | 0.8% |
| PANAMA | $7.8K | 1 | 0.2% |
Hetero Labs Limited exports Fluticasone to 4 countries. The largest destination is CHILE accounting for 90.5% of Hetero Labs Limited's Fluticasone shipments, followed by MOROCCO (8.5%) and DOMINICAN REPULIC (0.8%). These destinations reflect Hetero Labs Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Fluticasone from Hetero Labs Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER OF | MOROCCO | $1.3M | 30 |
| SEVEN PHARMA CHILE SPA | CHILE | $1.2M | 41 |
| TO THE ORDER OF., | CHILE | $662.7K | 25 |
| M STO THE ORDER OFSEVEN PHARMA CHILE SPA | CHILE | $100.0K | 2 |
| TO THE ORDER | CHILE | $100.0K | 2 |
| LABORATOIRES SOTHEMA | MOROCCO | $92.6K | 2 |
| M S TO THE ORDER OF SEVEN PHARMA CHILE | CHILE | $50.0K | 1 |
| M S TO THE ORER OFSEVEN PHARMA CHILE SPA | CHILE | $50.0K | 1 |
| SEVEN PHARMA CHILE SPA, | CHILE | $45.2K | 1 |
| TO THE ORDER OF.. | CHILE | $42.4K | 3 |
Hetero Labs Limited supplies Fluticasone to 11 buyers globally. The largest buyer is TO THE ORDER OF (MOROCCO), followed by SEVEN PHARMA CHILE SPA (CHILE) and TO THE ORDER OF., (CHILE). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Fluticasone Export Value and How Much Does Hetero Labs Limited Contribute?
India exported $145.4M worth of Fluticasone through 9,009 shipments from 239 suppliers to 123 countries, serving 664 buyers globally. Hetero Labs Limited contributes $4.5M to this total, accounting for 2.2% of India's Fluticasone exports. Hetero Labs Limited ships Fluticasone to 4 countries through 11 buyers.
What Is the Average Shipment Value for Hetero Labs Limited's Fluticasone Exports?
Hetero Labs Limited's average Fluticasone shipment value is $40.5K per consignment, based on 112 shipments totaling $4.5M. The largest destination is CHILE (90.5% of Hetero Labs Limited's Fluticasone exports).
How Does Hetero Labs Limited Compare to Other Indian Fluticasone Exporters?
Hetero Labs Limited ranks #2 among 239 Indian Fluticasone exporters with a 2.2% market share. The top 3 exporters are CIPLA LIMITED ($133.2M), HETERO LABS LIMITED ($4.5M), ZYDUS LIFESCIENCES LIMITED ($1.7M). Hetero Labs Limited processed 112 shipments to 4 destination countries.
What Fluticasone Formulations Does Hetero Labs Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| FLUSACORT SALMETEROL+FLUTICASONE PROPIONATE INHALER | $918.1K | 29 |
| FLUSACORT SALMETEROL +FLUTICASONE PROPIONATE INHALER | $382.9K | 8 |
| FLUSACORT SALMETEROL+FLUTICASONE PROPIONATE INHALERNOS | $213.1K | 12 |
| FLUSACORT SF 25 250 SALMETEROL 25 MCG FLUTICASONE PROPIONATE 250 MCG INHALER | $200.0K | 4 |
| FLUSACORT SALMETEROL 25 MCG + FLUTICASONE PROPIONATE 250 MCG INHALER | $200.0K | 4 |
| FLUSACORT SALMETEROL+FLUTICASONE PROPIONATE 25MCG+250MCG INHALER 120MD | $175.6K | 6 |
| FLUSACORT SALMETEROL FLUTICASONE PROPIONATE 25MCG 125MCG INHALER 120MD | $153.0K | 5 |
| FLUSACORT (SALMETEROL+FLUTICASONE PROPIONATE INHALER 120MD) | $150.0K | 3 |
| FLUSACORT (SALMETEROL+FLUTICASONE PROPIONATE 25MCG+250MCG INHALER120MD)NOS | $129.8K | 6 |
| FLUSACORT (SALMETEROL+FLUTICASONE PROPIONATE 25MCG+250MCG INHALER 120MD)NOS | $129.5K | 6 |
Hetero Labs Limited exports 30 distinct Fluticasone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is FLUSACORT SALMETEROL+FLUTICASONE PROPIONATE INHALER with 29 shipments worth $918.1K.
How Does Hetero Labs Limited Compare to Nearest Fluticasone Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | CIPLA LIMITED | $133.2M | 2,663 | 53 | $50.0K |
| 2 | HETERO LABS LIMITED ★ | $4.5M | 112 | 4 | $40.5K |
| 4 | ZYDUS LIFESCIENCES LIMITED | $1.7M | 93 | 8 | $17.9K |
| 5 | SAVA HEALTHCARE LIMITED | $1.1M | 711 | 7 | $1.5K |
Hetero Labs Limited ranks #2 among 239 Indian Fluticasone exporters. Average shipment value of $40.5K compared to the market average of $608.3K. The closest competitors by value are CIPLA LIMITED and ZYDUS LIFESCIENCES LIMITED.
Which Indian Ports Ship Fluticasone Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 2,008 | 22.3% |
| DELHI AIR | 1,273 | 14.1% |
| DELHI AIR CARGO ACC (INDEL4) | 1,244 | 13.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 982 | 10.9% |
| NHAVA SHEVA SEA (INNSA1) | 473 | 5.3% |
| Bombay Air | 426 | 4.7% |
| JNPT/ NHAVA SHEVA SEA | 342 | 3.8% |
| Delhi Air | 296 | 3.3% |
What Other Respiratory Products Does Hetero Labs Limited Export?
Hetero Labs Limited also exports these respiratory products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Hetero Labs Limited's Fluticasone Exports
The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.
Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.
The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.
Hetero Labs Limited — Regulatory Compliance & Quality Standards
Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.
About Hetero Labs Limited
Hetero Labs Limited exports 46 products worth $319.3M. Beyond Fluticasone, top products include Tenofovir, Dolutegravir, Ritonavir, Acyclovir, Valacyclovir. View the complete Hetero Labs Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Fluticasone — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Fluticasone shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 112 individual customs records matching Hetero Labs Limited exporting Fluticasone, covering 30 formulations to 4 countries via 11 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 123+ countries, 664+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Fluticasone Export Data from Hetero Labs Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Hetero Labs Limited's Fluticasone exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Hetero Labs Limited
Full Company Profile →
46 products · $319.3M total trade · 18 categories
Fluticasone Stats
Company Overview
Top Products by Hetero Labs Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Hetero Labs Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Fluticasone. For current shipment-level data, contact TransData Nexus.